Drug Trial Radar · NCT00090103
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
Last checked: Nov 20, 2026Latest source record: Feb 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,844
Actual
Start
Nov 2003
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 26, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually.
Conditions
- Prostatic Hyperplasia
Interventions
dutasteride 0.5mg once daily for 4 yearsDrug
combination or single agent
tamsulosin 0.4mg once daily for 4 yearsDrug
combination agent or single agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.Time frame: Years 1, 2, 3, and 4
- Number of Participants With AUR or BPH-related SurgeryTime frame: Baseline (Day 1) through Year 4
Locations
503 sites in 36 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Columbiana, Alabama
GSK Investigational Site
Hoover, Alabama
GSK Investigational Site
Anchorage, Alaska
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona, Arizona
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Concord, California
GSK Investigational Site
Glendora, California
GSK Investigational Site
Greenbrae, California
GSK Investigational Site
Irvine, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Laguna Woods, California
GSK Investigational Site
Los Angelas, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Modesto, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Vista, California
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Bay Pines, Florida
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Daytona Beach, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
New Smyrna Beach, Florida
GSK Investigational Site
Ocala, Florida
GSK Investigational Site
Orange City, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
Pinecrest, Florida
GSK Investigational Site
Saint Augustine, Florida
GSK Investigational Site
Spring Hill, Florida
GSK Investigational Site
St. Petersburg, Florida
Showing 40 of 503 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.